Organization Overview
Historical Acquisition Tree
acetylcysteine (mucomyst) (2017)
aprepitant (Emend) (2017)
cefepime (maxipeme) (2017)
cisatracurium (nimbex) (2020)
cyanocobalamin (berocca) (2022)
cyclophosphamide (cytoxan) (2023)
daptomycin (cubicin) (2017)
decitabine (dacogen) (2018)
desmopressin (ddavp) (2017)
dihydroergotamine (D.H.E. 45) (2018)
ephedrine (2023)
eptifibatide (integrilin) (2018)
esmolol (brevibloc) (2018)
fluorouracil (efudex) (2017)
fulvestrant (faslodex) (2019)
gemcitabine (gemzar) (2018)
leucovorin (2017)
linezolid (zyvox) (2017)
melphalan (alkeran) (2017)
methocarbamol (robaxin) (2017)
methylprednisolone (medrol) (2018)
naltrexone (revia) (2018)
neostigmine (bloxiverz) (2023)
nitroprusside (nipride) (2016)
oxytocin (syntocinon) (2018)
palonosetron (aloxi) (2018)
phenylephrine (Prefrin) (2020)
piperacillin (pipracil) (2021)
succinylcholine (anectine) (2021)
tazobactam (Zosyn) (2021)
thiamine (2017)
Key: Nichi-Iko Pharmaceutical Co., Ltd. (0) Acquired (4)
Key: Nichi-Iko Pharmaceutical Co., Ltd. (0) Acquired (1)
Arthritis (Phase 3)
Arthritis, Rheumatoid (Phase 3)